Trending Stock News

Spark Therapeutics, Inc. (ONCE) Analysts See $-1.74 EPS; Wells Fargo Advantage Multi-sector Income Fund (ERC) Has 1.1 Sentiment

The stock increased 0.31% or $0.04 during the last trading session, reaching $13. About 106,042 shares traded. Wells Fargo Advantage Multi-Sector Income Fund (ERC) has risen 9.57% since February 20, 2017 and is uptrending. It has underperformed by 7.13% the S&P500.

Analysts expect Spark Therapeutics, Inc. (NASDAQ:ONCE) to report $-1.74 EPS on February, 28.They anticipate $0.52 EPS change or 42.62% from last quarter’s $-1.22 EPS. After having $-1.90 EPS previously, Spark Therapeutics, Inc.’s analysts see -8.42% EPS growth. The stock decreased 0.89% or $0.49 during the last trading session, reaching $54.5. About 472,492 shares traded. Spark Therapeutics, Inc. (NASDAQ:ONCE) has risen 13.53% since February 20, 2017 and is uptrending. It has underperformed by 3.17% the S&P500.

Saba Capital Management L.P. holds 1.49% of its portfolio in Wells Fargo Advantage Multi-Sector Income Fund for 1.10 million shares. Shaker Financial Services Llc owns 133,250 shares or 0.95% of their US portfolio. Moreover, Selway Asset Management has 0.8% invested in the company for 103,115 shares. The Minnesota-based Sit Investment Associates Inc has invested 0.55% in the stock. Vident Investment Advisory Llc, a Georgia-based fund reported 474,596 shares.

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company has market cap of $2.02 billion. The Company’s products include voretigene neparvovec, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or biallelic mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. It currently has negative earnings. The company's products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A.

Among 24 analysts covering Spark Therapeutics (NASDAQ:ONCE), 15 have Buy rating, 2 Sell and 7 Hold. Therefore 63% are positive. Spark Therapeutics had 62 analyst reports since August 21, 2015 according to SRatingsIntel. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) has “Buy” rating given on Wednesday, August 2 by BMO Capital Markets. The company was initiated on Wednesday, March 30 by Goldman Sachs. J.P. Morgan downgraded the shares of ONCE in report on Wednesday, February 14 to “Hold” rating. The rating was maintained by Stifel Nicolaus on Monday, June 26 with “Buy”. The firm has “Buy” rating by Cowen & Co given on Wednesday, January 3. On Wednesday, August 2 the stock rating was maintained by Stifel Nicolaus with “Buy”. The firm has “Buy” rating by Jefferies given on Tuesday, July 11. The rating was downgraded by Wunderlich to “Hold” on Thursday, December 24. The firm has “Buy” rating by Chardan Capital Markets given on Wednesday, August 2. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) has “Buy” rating given on Friday, August 25 by Cantor Fitzgerald.

Investors sentiment increased to 2.94 in 2017 Q3. Its up 1.13, from 1.81 in 2017Q2. It increased, as 17 investors sold Spark Therapeutics, Inc. shares while 19 reduced holdings. 46 funds opened positions while 60 raised stakes. 33.64 million shares or 23.59% more from 27.22 million shares in 2017Q2 were reported. Bankshares Of America Corporation De stated it has 11,719 shares or 0% of all its holdings. Credit Suisse Ag holds 67,405 shares. Retirement Of Alabama reported 0.01% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Jennison Associates Ltd Liability Company owns 305,506 shares or 0.03% of their US portfolio. Moreover, Pictet Asset Ltd has 0.03% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE). Strs Ohio has invested 0% of its portfolio in Spark Therapeutics, Inc. (NASDAQ:ONCE). Ghost Tree Cap Ltd Liability Co accumulated 1.51% or 80,000 shares. Fred Alger Mgmt Inc holds 0.01% or 33,277 shares in its portfolio. Blackrock Inc holds 2.61 million shares. American Intl Grp Inc owns 17,862 shares for 0.01% of their portfolio. Tiaa Cref Investment Lc stated it has 78,957 shares. C World Wide Group Hldgs A S holds 52,349 shares or 0.07% of its portfolio. Moore Capital Management Ltd Partnership reported 35,000 shares stake. Envestnet Asset Mngmt has 0% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE) for 164 shares. 26,100 are held by Jefferies Group Inc Llc.

Leave a Reply

Your email address will not be published. Required fields are marked *